Roche to Acquire Spark Therapeutics for $4.3B

Shots:

• Roche acquires Spark Therapeutics, in all stock transaction for $114.50 /share in cash, making the total deal value $4.3B. Spark to receive premium of 122% based on its last day closing share price value i.e 22 February 2019
• The focus of the acquisition is to expand Roche’s footprints in genetic disorders including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases
• Spark therapeutics’ portfolio includes SPK-8011 & SPK-8016 for hemophilia A, SPK-9001 for haemophilia B, SPK-3006 for Pompe disease, SPK-1001 for CLN2 disease and Luxturna (voretigene neparvovec-rzyl) approved for confirmed biallelic RPE65 mutation-associated retinal dystrophy. The transaction is expected to close in the Q2’19  

Click here to read full press release/ article | Ref: Roche | Image: News Pharmaceutical